Latest news about Nephrocare Health Services
Nephrocare Health Services
708.70
+11.65(+1.67%)
Company Performance:
View Company Insights1D+1.67%
1M-0.62%
6M+27.01%
1Y0.00%
5Y0.00%
More news about Nephrocare Health Services
12Aug 26
Nephrocare Health Latest Results: Reaffirms 15%-20% Medium-Term Growth Guidance
Nephrocare Health Services has confirmed its medium-term growth prediction of 15% to 20% over the coming 3 to 5 years. The reaffirmation of this guidance range reflects the company's stated confidence in its business outlook over the specified horizon. No supplementary financial data or quarterly metrics were disclosed as part of this update.
12Aug 26
Nephrocare Health Services Q1FY27 revenue rises 24%, net profit up 35% YoY
Nephrocare Health Services posted Q1FY27 consolidated net profit of ₹320M vs ₹237M YoY, with revenue rising to ₹2.8B from ₹2.3B. Reported EBITDA stood at ₹603M (margin: 21.41%), while adjusted EBITDA grew 31% to ₹65.1 crore. Treatments rose 13.3% to 10.31 lakh, and international expansion continued across the Philippines, Uzbekistan, and Saudi Arabia.
05Aug 26
Nephrocare Health Services approves insider trading plans for share sales
Nephrocare Health Services Limited disclosed approved trading plans for CEO Rohit Singh and Sukaran Singh Saluja to sell 30,000 and 60,000 shares respectively between December 7-11, 2026. The sales are contingent on a minimum price of ₹700 per share, aligned with SEBI PIT Regulations.
24Jul 26
Nephrocare Health Services hosts Q1FY27 earnings call on Aug 12
Nephrocare Health Services Limited will host its Q1FY27 earnings call on August 12, 2026, at 10:00 AM IST. Chairman Vikram Vuppala, Group CEO Rohit Singh, and CFO Prashant Goenka will discuss unaudited standalone and consolidated results for the quarter ended June 30, 2026. The call complies with SEBI Listing Regulations and excludes unpublished price-sensitive information.
19Jul 26
Nephrocare Health Services AGM scheduled on Aug 12, 2026
Nephrocare Health Services Limited has announced its 17th Annual General Meeting for August 12, 2026, to be held virtually. The meeting will address the adoption of audited financial statements for the year ended March 31, 2026, and the re-appointment of Mr. Gaurav Sharma as Director. Shareholders will vote on the 'NephroPlus Employee Stock Option Scheme – 2026', involving up to 20,06,814 options, and clarificatory amendments to the remuneration of Chairman & Managing Director Mr. Vikram Vuppala. The AGM also seeks approval for the Promote Incentive Arrangement involving the Founder Promoter and specific investors.
09Jul 26
NephroPlus Sees Rs 70 Crore Block Trade on NSE/BSE at Rs 636.36 Per Share
A block trade worth Rs 70 crore was executed on NSE and BSE for approximately 11,00,000 shares of NephroPlus (nephrocare health services) at a price of Rs 636.36 per share. The transaction represents significant large-scale activity in the stock on the exchanges.
26Jun 26
Nephrocare unit acquires Philippines dialysis assets for PhP 151.6M
Nephrocare Health Care Services, Philippines Inc., a step-down wholly-owned subsidiary of Nephrocare Health Services Limited, acquired dialysis center assets in Orion, Bataan, Philippines, for PhP 151,600,000 via an Asset Transfer Agreement dated June 24, 2026.
24Jun 26
Nephrocare Unit Acquires Philippines Dialysis Center Assets for PhP 80,640,000
Nephrocare Health Services disclosed that its wholly-owned Philippines subsidiary entered an Asset Transfer Agreement on June 22, 2026, to acquire dialysis center assets from Pag-Asa Dialysis And Diagnostic Center for PhP 80,640,000. The transaction is not a related party deal, involves no special rights, and supports the company's strategy to expand its international healthcare presence.
23Jun 26
Nephrocare Health Services approves ESOP 2026 and INR 70 Cr Saudi collateral
Nephrocare Health Services Ltd approved the NephroPlus Employee Stock Option Scheme 2026, covering 20,06,814 options or 2% of paid-up capital, and sanctioned INR 70 Crore collateral support for its Saudi subsidiary, NephroPlus Kidney Services Company, replacing a prior approval for a joint venture entity.
20Jun 26
Edoras confirms no encumbrance on Nephrocare shares in FY26
Edoras Investment Holdings Pte. Ltd, a promoter of Nephrocare Health Services Limited, confirmed no encumbrance on the target company's shares for FY ended March 31, 2026, under SEBI regulations. The disclosure excludes previously reported encumbrances.
20Jun 26
Nephrocare trading window closed from June 22 until Q1FY27 results
Nephrocare Health Services Ltd has closed its trading window for designated persons effective June 22, 2026, due to unpublished price sensitive information including Q1FY27 results. The window will reopen 48 hours after the unaudited financial results for the quarter ended June 30, 2026 are declared, in compliance with SEBI regulations.
19Jun 26
Investcorp confirms no encumbrance on Nephrocare shares in FY26
Investcorp Private Equity Fund II declared that no encumbrance was created on the shares of Nephrocare Health Services Limited during FY26, other than those previously disclosed. The filing was submitted to BSE and NSE in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
18Jun 26
Nephrocare Health Services cancels analyst meetings on June 18-19
Nephrocare Health Services has cancelled its analyst and institutional investor meetings scheduled for June 18 and June 19, 2026, citing unavoidable exigencies. The company informed the stock exchanges on June 17, 2026, under Regulation 30(6) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
11Jun 26
Nephrocare unit acquires Philippines dialysis assets for PhP 32.64 million
Nephrocare Health Services' Philippines subsidiary acquired dialysis center assets for PhP 32,640,000 from Amica Healthcare System Corporation via an Asset Transfer Agreement dated June 09, 2026. The transaction, disclosed under Regulation 30 of SEBI Listing Regulations, is not a related party transaction and includes no special rights.
28May 26
Nephrocare Health Services to attend investor conference on June 11
Nephrocare Health Services Limited has scheduled a virtual analyst and institutional investor conference for June 11, 2026, hosted by Choice Broking. The meeting will focus on publicly available information, with no unpublished price sensitive information to be discussed, pursuant to Regulation 30 of the SEBI Listing Regulations.
28May 26
Nephrocare Health Services to attend BoFA investor meet on June 04
Nephrocare Health Services Limited announced its participation in the BoFA Healthcare Tour, an investor conference hosted by Bank of America on June 04, 2026, in Hyderabad. The event features group and one-on-one meetings, with discussions restricted to publicly available information. The disclosure, signed by Company Secretary Kishore Kathri, was made under Regulation 30 of the SEBI Listing Regulations.
27May 26
Nephrocare revenue rises 32.2%, PAT surges 74.6% in FY26
Nephrocare Health Services reported a 32.2% increase in FY26 revenue to ₹998.8 crore, driven by a 16.6% rise in treatment volumes and a 13.3% increase in revenue per treatment. Adjusted PAT surged 74.6% to ₹128.3 crore, with Adjusted EBITDA margins expanding to 23.8%. The company's international revenue contribution grew to 42%, and it maintains a medium-term revenue CAGR guidance of 15-20%.
27May 26
Nephrocare acquires Philippines dialysis assets for PHP 72.2 million
Nephrocare Health Services Limited expanded its renal care presence by acquiring dialysis center assets in the Philippines through its subsidiary. The company signed two Asset Transfer Agreements worth a total of PHP 72.2 million, approximately INR 11.24 Crores, with Northern Mindanao Dialysis Clinic Inc. and Aliaga Hemodialysis Centre Inc. The transactions, executed on May 26, 2026, are arm's length deals and do not involve related parties.
27May 26
Nephrocare Health Services investor meet on June 15-16
Nephrocare Health Services Limited will conduct a non-deal roadshow for analysts and institutional investors on June 15 and 16, 2026, in Mumbai. Hosted by Citi, the event will feature group and one-on-one interactions starting at 10:00 A.M. IST. The company confirmed that no unpublished price sensitive information will be shared during the meeting.
27May 26
Nephrocare Health Services to attend investor meet on June 18-19
Nephrocare Health Services Limited announced its participation in the HSBC Singapore Conference on June 18-19, 2026, in Mumbai. Officials will hold group and one-on-one meetings with analysts and investors based on publicly available information. The company confirmed that no unpublished price sensitive information will be discussed during these sessions.
27May 26
Nephrocare incorporates Kazakhstan subsidiary to expand dialysis network
Nephrocare Health Services incorporated a step-down subsidiary, NEPHROPLUS HEALTH SERVICES KAZAKHSTAN LLP, on May 26, 2026, to expand its dialysis network. The entity has a charter capital of KZT 5,000,000 and is wholly controlled indirectly through Nephrocare Health Services International Pte. Ltd.
23May 26
Nephrocare to attend investor meet on June 2
Nephrocare Health Services announced its participation in an investor conference on June 2, 2026, organized by Axis Capital in Mumbai. The meeting will involve group and one-on-one discussions based on publicly available information, with no UPSI to be shared.
20May 26
Nephrocare FY26 net loss at ₹80.60 million
Nephrocare Health Services Limited reported a standalone net loss of ₹80.60 million for the financial year ended March 31, 2026, against a net profit of ₹342.36 million in the previous year, while consolidated net profit increased to ₹768.40 million. Revenue from operations grew to ₹6,297.43 million on a standalone basis and ₹9,988.45 million on a consolidated basis. The board approved further investments in overseas subsidiaries and re-appointed M/s. BDO India LLP as Internal Auditor.
19May 26
Nephrocare Health Services Announces Investment of Up to 100 Million Rupees in Nepal Subsidiary
Nephrocare Health Services has announced an investment of up to 100 million rupees in Nephrocare Health Services Nepal. The announcement highlights the company's cross-border capital allocation toward its Nepal-based entity. No additional financial metrics or timelines were disclosed alongside this announcement.
13May 26
Nephrocare Unit Acquires Philippines Dialysis Center Assets for PHP 89.6 Million
Nephrocare Health Services Limited disclosed that its step-down wholly-owned subsidiary, Nephrocare Health Care Services, Philippines Inc., has acquired dialysis center assets in Orani, Bataan, Philippines for PHP 89,600,000.00 through an Asset Transfer Agreement dated May 12, 2026, with Orani Hemodialysis Center Inc. The transaction, made under Regulation 30 of SEBI LODR, involves no special rights and is not classified as a related party transaction.
05May 26
Nephrocare Health Services Schedules Q4FY26 Earnings Conference Call for May 20, 2026
Nephrocare Health Services has scheduled its Q4FY26 Results Conference Call for May 20, 2026, at 16:00 IST, hosted by ICICI Securities. Senior leadership including the CMD, Co-Founder, Group CEO, and Group CFO will represent the company. The call will cover audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, with discussions limited to publicly available information.
04May 26
Nephrocare Health Services Schedules Board Meeting on May 19, 2026 to Approve Q4 and FY26 Financial Results
Nephrocare Health Services Limited has informed stock exchanges of a Board of Directors meeting scheduled for May 19, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The intimation was issued on May 04, 2026, under reference NEPHROPLUS/SE/030. The trading window for designated persons and their immediate relatives has been closed from April 01, 2026 till May 21, 2026 (both days inclusive), in line with applicable SEBI regulations.
03Apr 26
Nephrocare Health Services Designates CFO Prashant Goenka as Chief Risk Officer
Nephrocare Health Services Limited has designated Mr. Prashant Vinodkumar Goenka as Chief Risk Officer effective April 03, 2026, in addition to his existing CFO role. The Board of Directors approved the appointment through circular resolution on the same date. Mr. Goenka brings over 20 years of financial services expertise from leading institutions including HSBC, Bank of America, and JP Morgan Chase, with experience across USA, Philippines, and India.
02Apr 26
Nephrocare Health Services Files Writ Petition Challenging ₹2.51 Crore GST Demand
Nephrocare Health Services Limited filed a writ petition on April 02, 2026 challenging GST orders worth ₹2.51 crore before the Hon'ble High Court of Jammu & Kashmir and Ladakh at Srinagar. The dispute involves alleged turnover mismatch between Form 26AS and GST returns for FY 2020-21, with demands comprising ₹1.46 crore tax, ₹0.90 crore interest, and ₹0.15 crore penalty. The company maintains its dialysis services are GST-exempt and contests the demand's validity while facing parallel recovery proceedings.
16Mar 26
Nephrocare Health Services Limited schedules investor conference for March 23, 2026 at Dam Capital Conference
Nephrocare Health Services Limited has announced its participation in Dam Capital Conference scheduled for March 23, 2026 in Mumbai, starting at 10:00 A.M. IST. The company notified BSE and NSE under SEBI Listing Regulations about the investor meetings, which will include both group and one-on-one sessions with analysts and institutional investors. Company officials confirmed that discussions will be based solely on publicly available information with no unpublished price sensitive information to be shared.
16Mar 26
InCred Securities Initiates Add Rating on Nephrocare Health Services with ₹613 Target Price
InCred Securities has initiated coverage on Nephrocare Health Services with an Add rating and ₹613 target price. The brokerage highlighted the company's market leadership in the growing dialysis segment, strong operational performance, and scalable asset-light tie-up model that supports margins. While acknowledging execution risks, InCred remains positive on the company's growth potential in the expanding dialysis industry.
Industry Peers
Dr. Lal Path Labs
Vijaya Diagnostic Centre
Metropolis Healthcare
Thyrocare TechnologiesNephrocare Health Services
Krsnaa Diagnostics
Suraksha Diagnostic
3B BlackBio DX
One Global Service Provider
Health X Platform
1,901.50
(+1.28%)
1,497.60
(+0.29%)
579.75
(-1.52%)
570.15
(-1.04%)
708.70
(+1.67%)
563.60
(+0.64%)
338.10
(+1.70%)
1,517.90
(+3.96%)
524.90
(-3.23%)
298.70
(-0.53%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
